190 related articles for article (PubMed ID: 23261499)
1. Neurochemical profiles of some novel psychoactive substances.
Iversen L; Gibbons S; Treble R; Setola V; Huang XP; Roth BL
Eur J Pharmacol; 2013 Jan; 700(1-3):147-51. PubMed ID: 23261499
[TBL] [Abstract][Full Text] [Related]
2. The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats.
Brandt SD; Walters HM; Partilla JS; Blough BE; Kavanagh PV; Baumann MH
Psychopharmacology (Berl); 2020 Dec; 237(12):3703-3714. PubMed ID: 32875347
[TBL] [Abstract][Full Text] [Related]
3. Neurochemical binding profiles of novel indole and benzofuran MDMA analogues.
Shimshoni JA; Winkler I; Golan E; Nutt D
Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):15-24. PubMed ID: 27650729
[TBL] [Abstract][Full Text] [Related]
4. Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs).
Luethi D; Trachsel D; Hoener MC; Liechti ME
Neuropharmacology; 2018 May; 134(Pt A):141-148. PubMed ID: 28720478
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of mephedrone analogs and related new psychoactive substances.
Luethi D; Kolaczynska KE; Docci L; Krähenbühl S; Hoener MC; Liechti ME
Neuropharmacology; 2018 May; 134(Pt A):4-12. PubMed ID: 28755886
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of novel psychoactive benzofurans.
Rickli A; Kopf S; Hoener MC; Liechti ME
Br J Pharmacol; 2015 Jul; 172(13):3412-25. PubMed ID: 25765500
[TBL] [Abstract][Full Text] [Related]
7. Combined in vitro and in silico approaches to the assessment of stimulant properties of novel psychoactive substances - The case of the benzofuran 5-MAPB.
Sahai MA; Davidson C; Khelashvili G; Barrese V; Dutta N; Weinstein H; Opacka-Juffry J
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Apr; 75():1-9. PubMed ID: 27890676
[TBL] [Abstract][Full Text] [Related]
8. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones.
Rickli A; Hoener MC; Liechti ME
Eur Neuropsychopharmacol; 2015 Mar; 25(3):365-76. PubMed ID: 25624004
[TBL] [Abstract][Full Text] [Related]
9. Effects of the new psychoactive substances diclofensine, diphenidine, and methoxphenidine on monoaminergic systems.
Luethi D; Hoener MC; Liechti ME
Eur J Pharmacol; 2018 Jan; 819():242-247. PubMed ID: 29225192
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.
Han DD; Gu HH
BMC Pharmacol; 2006 Mar; 6():6. PubMed ID: 16515684
[TBL] [Abstract][Full Text] [Related]
11. Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay.
Zwartsen A; Verboven AHA; van Kleef RGDM; Wijnolts FMJ; Westerink RHS; Hondebrink L
Toxicol In Vitro; 2017 Dec; 45(Pt 1):60-71. PubMed ID: 28506818
[TBL] [Abstract][Full Text] [Related]
12. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs).
Rickli A; Luethi D; Reinisch J; Buchy D; Hoener MC; Liechti ME
Neuropharmacology; 2015 Dec; 99():546-53. PubMed ID: 26318099
[TBL] [Abstract][Full Text] [Related]
13. Interaction of cis-(6-benzhydrylpiperidin-3-yl)benzylamine analogues with monoamine transporters: structure-activity relationship study of structurally constrained 3,6-disubstituted piperidine analogues of (2,2-diphenylethyl)-[1-(4-fluorobenzyl)piperidin-4-ylmethyl]amine.
Kolhatkar RB; Ghorai SK; George C; Reith ME; Dutta AK
J Med Chem; 2003 May; 46(11):2205-15. PubMed ID: 12747792
[TBL] [Abstract][Full Text] [Related]
14. Further characterisation of the interaction of haloperidol metabolites with neurotransmitter transporters in rat neuronal cultures and in transfected COS-7 cells.
Siebert GA; Pond SM; Bryan-Lluka LJ
Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):255-64. PubMed ID: 10731037
[TBL] [Abstract][Full Text] [Related]
15. Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
Cao J; Kulkarni SS; Husbands SM; Bowen WD; Williams W; Kopajtic T; Katz JL; George C; Newman AH
J Med Chem; 2003 Jun; 46(13):2589-98. PubMed ID: 12801223
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives.
Simmler LD; Rickli A; Schramm Y; Hoener MC; Liechti ME
Biochem Pharmacol; 2014 Mar; 88(2):237-44. PubMed ID: 24486525
[TBL] [Abstract][Full Text] [Related]
17. The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter.
Pifl C; Reither H; Hornykiewicz O
Eur J Pharmacol; 2015 May; 755():119-26. PubMed ID: 25771452
[TBL] [Abstract][Full Text] [Related]
18. Validation of a fluorescence-based high-throughput assay for the measurement of neurotransmitter transporter uptake activity.
Jørgensen S; Nielsen EØ; Peters D; Dyhring T
J Neurosci Methods; 2008 Mar; 169(1):168-76. PubMed ID: 18222006
[TBL] [Abstract][Full Text] [Related]
19. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro.
Madras BK; Xie Z; Lin Z; Jassen A; Panas H; Lynch L; Johnson R; Livni E; Spencer TJ; Bonab AA; Miller GM; Fischman AJ
J Pharmacol Exp Ther; 2006 Nov; 319(2):561-9. PubMed ID: 16885432
[TBL] [Abstract][Full Text] [Related]
20. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.
Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP
J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
